A prediction model of liver fat fraction and presence of non-alcoholic fatty liver disease (NAFLD) among patients with overweight or obesity

被引:2
作者
Chen, Jie [1 ]
Yue, Jiang [1 ]
Fu, Jingjing [1 ]
He, Shengyun [2 ]
Liu, Qianjing [1 ]
Yang, Minglan [1 ]
Zhang, Wang [1 ]
Xu, Hua [1 ]
Lu, Qing [2 ,4 ]
Ma, Jing [1 ,3 ]
机构
[1] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Endocrinol & Metab, Shanghai 200127, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Radiol, Shanghai 200127, Peoples R China
[3] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Endocrinol & Metab, 160 Pujian Rd, Shanghai 200127, Peoples R China
[4] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Radiol, 160 Pujian Rd, Shanghai 200127, Peoples R China
关键词
Non-alcoholic fatty liver disease (NAFLD); Magnetic resonance imaging proton density fat fraction (MRI-PDFF); Obese; Overweight; HEPATIC STEATOSIS; DIAGNOSIS; PREVALENCE; BIOPSY;
D O I
10.1507/endocrj.EJ23-0227
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The global prevalence of non-alcoholic fatty liver disease (NAFLD) has attained a level of 25.24%. The prevalence of NAFLD in China has exhibited an upward trajectory in parallel with the increasing incidence of obesity over the preceding decade. In order to comprehensively assess hepatic lipid deposition in individuals with overweight or obesity, we have devised a pioneering prognostic formula that capitalizes on clinical parameters. To this end, we have conducted a cross-sectional cohort study involving 149 overweight or obese subjects. Magnetic resonance imaging proton density fat fraction (MRI-PDFF) has been employed to evaluate the extent of liver fat accumulation. Through univariate analysis, we have identified potential factors, and the definitive elements in the prediction model were selected utilizing the forward stepwise regression algorithm. The Shang Hai Steatosis Index (SHSI) incorporates alanine aminotransferase (ALT), aspartate aminotransferase (AST), fasting insulin, and 1-h postload glycaemic levels, thereby furnishing the capability to predict NAFLD with an area under the receiver operator characteristic (AUROC) of 0.87. By establishing a threshold value of 10.96, determined through Youden's index, we have achieved a sensitivity of 69.57% and a specificity of 88.24%. The Spearman correlation coefficient between liver fat fraction ascertained by MRI-PDFF and that predicted by the SHSI equation amounts to 0.74. Consequently, the SHSI equation affords a dependable means of predicting the presence of NAFLD and liver fat accumulation within the overweight and obese population.
引用
收藏
页码:977 / 985
页数:9
相关论文
共 50 条
[21]   Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD) [J].
Rong, Li ;
Zou, Junyan ;
Ran, Wei ;
Qi, Xiaohong ;
Chen, Yaokai ;
Cui, Hongjuan ;
Guo, Jinjun .
FRONTIERS IN ENDOCRINOLOGY, 2023, 13
[22]   Pathology of non-alcoholic fatty liver disease [J].
Cataldo, Ivana ;
Sarcognato, Samantha ;
Sacchi, Diana ;
Cacciatore, Matilde ;
Baciorri, Francesca ;
Mangia, Alessandra ;
Cazzagon, Nora ;
Guido, Maria .
PATHOLOGICA, 2021, 113 (03) :194-202
[23]   Serum adipokine levels in overweight patients and their relationship with non-alcoholic fatty liver disease [J].
Abenavoli, L. ;
Luigiano, C. ;
Guzzi, P. H. ;
Milic, N. ;
Morace, C. ;
Stelitano, L. ;
Consolo, P. ;
Miraglia, S. ;
Fagoonee, S. ;
Virgilio, C. ;
Luzza, F. ;
De Lorenzo, A. ;
Pellicano, R. .
PANMINERVA MEDICA, 2014, 56 (02) :189-193
[24]   Non-alcoholic fatty liver disease [J].
Maurice, James ;
Manousou, Pinelopi .
CLINICAL MEDICINE, 2018, 18 (03) :245-250
[25]   Non-Alcoholic Fatty Liver Disease [J].
Engin, Atilla .
OBESITY AND LIPOTOXICITY, 2017, 960 :443-467
[26]   Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors [J].
Kotronen, Anna ;
Peltonen, Markku ;
Hakkarainen, Antti ;
Sevastianova, Ksenia ;
Bergholm, Robert ;
Johansson, Lina M. ;
Lundbom, Nina ;
Rissanen, Aila ;
Ridderstrale, Martin ;
Groop, Leif ;
Orho-Melander, Marju ;
Yki-Jarvinen, Hannele .
GASTROENTEROLOGY, 2009, 137 (03) :865-872
[27]   Terpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy [J].
Yao, Pengyu ;
Liu, Yajuan .
MOLECULES, 2023, 28 (01)
[28]   Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) [J].
Choudhary, Narendra Singh ;
Duseja, Ajay .
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 6
[29]   Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review [J].
Riazi, Kiarash ;
Swain, Mark G. ;
Congly, Stephen E. ;
Kaplan, Gilaad G. ;
Shaheen, Abdel-Aziz .
NUTRIENTS, 2022, 14 (21)
[30]   Agai improves non-alcoholic fatty liver disease (NAFLD) induced by fructose [J].
de Freitas Carvalho, Mayara Medeiros ;
Teixeira Reis, Larissa Lelis ;
Macedo Lopes, Juliana Marcia ;
Lage, Nara Nunes ;
da Costa Guerra, Joyce Ferreira ;
Zago, Helena Porto ;
Bonomo, Larissa de Freitas ;
Pereira, Renata Rebeca ;
de Lima, Wanderson Geraldo ;
Silva, Marcelo Eustaquio ;
Pedrosa, Maria Lucia .
NUTRICION HOSPITALARIA, 2018, 35 (02) :318-325